
Mark Christopher Markowski MD
Instructor, Medicine, Johns Hopkins University School of Medicine
Join to view full profile
5255 Loughboro Road NorthwestBuilding BWashington, DC 20016
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Markowski, MD is an oncologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Virginia, and Pennsylvania. He is affiliated with Sibley Memorial Hospital, Johns Hopkins Hospital, and Johns Hopkins Bayview Medical Center.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Georgetown University School of MedicineClass of 2009
Certifications & Licensure
DC State Medical License 2015 - 2027
MD State Medical License 2012 - 2027
VA State Medical License 2022 - 2026
PA State Medical License 2020 - 2022
NY State Medical License 2011 - 2013
Publications & Presentations
PubMed
- 10 citationsDigital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.Mark C Markowski, Yi Ren, Meghan Tierney, Trevor J Royce, Rikiya Yamashita
European Urology Oncology. 2025-06-01 - 3 citationsAssociation of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.Etan R Aber, Michael A Carducci, Channing J Paller, Sam R Denmeade, Kelli Rourke
The Prostate. 2025-03-01 - 2 citationsBipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.Elizabeth U Tran, Eric Royz, Kyra Yamamoto, Samantha Marley, Alexander Song
The Prostate. 2025-01-01
Press Mentions
Panel Issues New Guidelines for Advanced Prostate CancerJanuary 13th, 2025
Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
COMBAT-CRPC Points to Potential of Combining BAT, NivolumabMay 6th, 2021









